Nutex Health (NUTX) Proxy Filing summary

Executive summary

• Annual meeting scheduled for July 14, 2025, to address key governance and compensation matters.

• Supplement corrects typographical errors in the original proxy statement, with all other information unchanged.

Voting matters and shareholder proposals

• Shareholders to re-elect six directors and elect one new director for one-year terms expiring at the 2026 annual meeting.

• Advisory vote on executive compensation included.

• Proposal to amend the 2023 Equity Incentive Plan to increase shares available by 1,100,000 and allow annual automatic increases.

• Ratification of Grant Thornton LLP as independent auditor for fiscal year ending December 31, 2025.

• Other business may be considered if properly brought before the meeting.

Board of directors and corporate governance

• Board nominees include six current members and one new candidate, Frank E. Jaumot.

• Directors to serve until the 2026 annual meeting or until successors are elected and qualified.